Four years after the British coalition government of David Cameron unveiled efforts to fend off criticism that it was failing to provide expensive new cancer drugs, the strains in the system are again beginning to show.
In 2010, it created the Cancer Drugs Fund to pay for medicines rejected as not cost effective by the National Institute for Health and Care Excellence (Nice). Yet the fund not only undermined Nice’s authority; it has also run into difficulties after significantly overspending its budget of £200m a year.
By Andrew Jack, FT
To read the full article please visit this link and register with FT.com www.ft.com/cms/s/0/2e417874-1bcf-11e4-9db1-00144feabdc0.html#ixzz3EmY7LA9e
